|
At the beginning of the year, Nutrition 21 submitted a qualified health claim linking chromium picolinate with a reduced risk of insulin resistance, type 2 diabetes and related disease conditions to the FDA.
Trials by the company have found daily supplementation of up to 1,000 mcg of chromium, as chromium picolinate alone or in combination with other therapies, helps reduce the risk of type 2 diabetes and other health conditions associated with insulin resistance.
The rapidly growing incidence of type 2 diabetes in the US (almost 1 million new cases of diabetes are diagnosed every year) has encouraged Nutrition 21 to focus on chromium's effects on insulin over recent months.
Approximately 95 million Americans have some degree of insulin resistance, according to the firm, which holds patents for the therapeutic use of chromium picolinate in addressing insulin resistance and type 2 diabetes.
|